UroAlerts - Prostate Cancer Weekly

May 12, 2026

Videos

Peer-to-Peer Clinical Conversations

AR Degraders, T-Cell Engagers, and EZH2 Inhibitors in Prostate Cancer Pipeline - Maha Hussain

Maha Hussain

Maha Hussain surveys emerging prostate cancer therapies across disease states.

Examining the Role of Metastasis-Directed Therapy Alone Versus Combined Approaches in Oligometastatic Prostate Cancer - Kosj Yamoah

Kosj Yamoah

Kosj Yamoah reviews metastasis-directed therapy for oligometastatic prostate cancer.

Beyond the Abstracts

A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO - Beyond the Abstract

A Prospective Provincial Registry of 18F-PSMA PET/CT for Recurrent Prostate Cancer: Results for 4,135 Men - Beyond the Abstract

Conference Coverage

APCCC 2026: Neuroendocrine Prostate Cancer - Treatment Options in 2026 and Hope for New Treatments?

APCCC 2026: Are There Patients with mCRPC Who May Benefit from Immunotherapy?

APCCC 2026: How to Select Patients with mHSPC for ADT plus an ARPI plus a Targeted Therapy (PARP or AKT Inhibition)?

APCCC 2026: Debate: Early Salvage Radiotherapy Is Equivalent to Adjuvant Radiotherapy in Patients with High-Risk Localized or Locally Advanced Disease: Pro

APCCC 2026: PSA Recurrence After Radiotherapy – When and How to React?

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Syncromune®, Inc. Presents Innovative SYNC-T Combination Immunotherapy Approach at Major European Interventional Oncology Conference

The Value of Systematic Versus Targeted Sampling in Prostate Cancer Detection and the Identification of Adverse Pathologic Features: A Retrospective Review of Over 1400 Combined Prostate Biopsies.

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial.

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Prostate Cancer Detection on Micro-Ultrasound Raw Data Using a Deep Learning Neural Network.

Single Port Robotic Radical Prostatectomy: A Propensity-matched Comparison of Transvesical Versus Extraperitoneal Approaches from the Single Port Advanced Research Consortium.

68Ga-PSMA-11 PET/CT for Detecting Biochemical Recurrence after Radical Prostatectomy in a Racially Diverse Population with Low PSA Levels.

Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review.

Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancer.

Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.

Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study.

Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E.

Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy - Beyond the Abstract

¹⁷⁷lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.

Patient Preferences for Treatment of Intermediate-Risk Prostate Cancer: A Discrete Choice Experiment.

The Experiences and Perspective of Partners of Men With Prostate Cancer in Ireland: A Qualitative Descriptive Study.

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Outcomes of Radiotherapy With or Without Dose Escalation to Lymph Node Metastases Detected by PET PSMA or Conventional Imaging in Node-Positive Prostate Cancer: A Real-World Multicenter Propensity Score-Matched (PRIMENOD) Analysis.

Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis.

Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.

The Outcome of Immediate Adjuvant Postoperative External Beam Radiotherapy Versus Observation Alone After Radical Prostatectomy in High-Risk Prostate Cancer: A Meta Analysis.

Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC